GCP · authorities · 4 minutes reading

Clinical trials digest

GCP, FDA, EMA, and what inspectors read

ICH E6(R3) applies in the EU and is FDA final guidance. EMA computerised-systems guidance and 21 CFR Part 11 decide how a login, a signature, and an audit trail must look.

GCPFDAEMAInspection
← All articles

4 min

Reading time

EU+US

Doctors and sites

1 record

Drug, device, IVD

GCP is a duty, not a logo

ICH E6(R3) is the current GCP text. It applies in the EU and was published as FDA final guidance in September 2025. Annex 1 is in force in Europe from July 2025. Annex 2 follows. The point is not a certificate on the wall. The point is that an investigator can show control of the study at their site, that a sponsor can show control of vendors, and that a computerized system can show who did what, when, and why. ValidTrials is designed against that text. We are registered with EOF and run studies as a CRO under it. Inspectors read the trail, not the brochure.

GCP is a duty, not a logo

Full article for doctors, investigators, and readers who follow clinical trials.

What a computerized system must show

EMA’s guidance on computerized systems and 21 CFR Part 11 ask for the same family of evidence: unique users, access control, audit trail, backup, validated operation, and electronic signatures that are attributable. ALCOA++ is the shorthand: attributable, legible, contemporaneous, original, accurate, plus complete, consistent, enduring, available. A shared login fails that list. An Excel file emailed at the end of the week fails contemporaneous. A vendor who cannot export the trail in an open format fails enduring. This digest names those failures because sites and sponsors still buy them.

Inspection questions we hear

Show me the current protocol version this participant was on. Show me who consented them, and which form. Show me the query that changed this laboratory value. Show me the delegation log on that date. Show me the backup and restore. Show me that the person who signed was the person who logged in. None of those questions require a slide about innovation. They require a record. ValidTrials is built so we and the investigator can answer them from the same system the site used during the visit, not from a reconstruction after the letter arrived.

Inspection questions we hear

Full article for doctors, investigators, and readers who follow clinical trials.

EOF, EMA, FDA, notified bodies

We are registered with EOF. Studies may also be read by EMA, national competent authorities, FDA, and, for devices and IVDs, notified bodies. The clocks and the forms differ. The expectation that the computerized system is under control does not. One clinical record that can produce more than one package is how a small sponsor survives that map. Two databases and a hope is how inspection findings are born. We will keep writing the map as the guidance moves, without pretending that software is the conclusion of the study.

Validated system, unvalidated product

A computerized system can be validated for its intended use. A product under study cannot be declared clinically validated by that system. Mixing those two sentences is how marketing gets sponsors into trouble. ValidTrials will hold the evidence. A named person will sign the analysis on a locked snapshot. The newsletter exists in part to keep those sentences apart for doctors, quality leads, and regulatory affairs.

Validated system, unvalidated product

Full article for doctors, investigators, and readers who follow clinical trials.

Read more from the digest.

Subscribe, or bring us the protocol.

The digest is for doctors and trial readers. The study conversation starts with us.